Pyrilutamide for Hair Loss: New Topical Research

For decades, the treatment options for androgenetic alopecia have centered on two mechanisms: blocking the enzyme that creates DHT (finasteride, dutasteride) or stimulating follicle growth through other pathways (minoxidil). Pyrilutamide, also known as KX-826, introduces a third approach. Developed by Kintor Pharmaceutical in Suzhou, China, this topical compound targets the androgen receptor itself, blocking DHT from binding at the follicle without reducing DHT levels elsewhere in the body. Phase II trial results are encouraging, Phase III trials are underway, and a growing number of hair loss patients are paying close attention.

Track any treatment from day one

HairLossTracker gives you a structured framework for documenting your response to any hair loss treatment, including emerging therapies. Consistent photos, logs, and timelines help you and your dermatologist evaluate what is working.

Use the BaldingAI hair tracking app to save one baseline session now, compare monthly checkpoints later, and keep one clear record for your next treatment or dermatologist decision.

Start Tracking In BaldingAITry free tools or compare the app first

How pyrilutamide works: receptor-level blocking

To understand what makes pyrilutamide different, you need to understand how existing treatments operate. Finasteride inhibits the enzyme 5-alpha reductase, which converts testosterone into DHT. This reduces serum DHT levels by about 70%. The approach works well for many men, but because it reduces DHT systemically, it can cause side effects related to low DHT in other tissues, including sexual side effects reported by a subset of users. For a full breakdown of how finasteride works over time, see our finasteride results timeline.

Pyrilutamide takes a fundamentally different approach. Instead of reducing DHT production, it blocks the androgen receptor at the follicle. Specifically, it is classified as an androgen receptor degrader (ARD). When applied topically to the scalp, it binds to androgen receptors in hair follicle cells and promotes their degradation. With fewer functional androgen receptors available, DHT cannot bind and trigger the miniaturization cascade that shortens the anagen phase and thins hair over successive cycles.

The critical distinction: your serum DHT levels remain unchanged. The testosterone-to-DHT conversion continues normally throughout the body. Only the follicles exposed to the topical application lose their ability to respond to DHT. This is analogous to the difference between topical and oral finasteride, but taken a step further. Topical finasteride reduces DHT locally with some systemic absorption. Pyrilutamide does not reduce DHT at all. It simply makes the receptor unavailable.

Phase II trial results: what the data shows

The key Phase II trial, published in the Journal of the American Academy of Dermatology (2022), enrolled 123 Chinese men with androgenetic alopecia. Participants applied either 0.5% pyrilutamide solution or a vehicle placebo twice daily for 24 weeks. The primary endpoint was change in non-vellus hair count per cm² in a target area.

The results: the pyrilutamide group showed an increase of 22.73 hairs per cm² compared to placebo over the 24-week period. To put that in context, published finasteride trials typically show increases of 15-25 hairs per cm² over 12-24 months, though direct comparison across different trials with different populations is inherently imprecise. The pyrilutamide result at 24 weeks is promising, but it comes from a relatively small sample of 123 participants, all Chinese men, which limits how broadly the findings can be applied.

The safety profile in the Phase II trial was favorable. No significant systemic antiandrogenic effects were reported. The most common adverse events were mild application-site reactions (redness, dryness, itching), which occurred at similar rates in both the treatment and placebo groups. Serum hormone panels, including testosterone and DHT levels, showed no statistically significant changes in the treatment group compared to placebo. This is the finding that makes pyrilutamide most interesting from a side-effect perspective.

Phase III trials: current status

Kintor Pharmaceutical has Phase III trials underway in China for both male and female androgenetic alopecia. The Chinese male AGA Phase III trial is the most advanced, with interim results expected based on Kintor's public disclosures. Separate Phase III trials for female pattern hair loss are also enrolling in China, which is notable because the female AGA treatment market has far fewer FDA-approved options than the male market.

In the United States, Kintor initiated a Phase III trial in 2023. This trial is critical because FDA approval requires Phase III data from US-based (or FDA-accepted international) trials. The US trial uses a larger, more diverse patient population than the Phase II Chinese cohort. Results from this trial will determine whether pyrilutamide can be submitted for FDA review and, if approved, prescribed in the US market. As of early 2026, the US Phase III trial is still enrolling or in its treatment period, with no published results yet.

The timeline from here to potential availability matters for anyone considering this treatment. Even in the best case, FDA review typically takes 12-18 months after Phase III data submission. If the US Phase III trial completes enrollment and treatment by late 2026, results analysis and NDA filing could push potential FDA approval to 2028 or beyond. This is a realistic, not pessimistic, estimate based on standard regulatory timelines.

How pyrilutamide compares to existing treatments

vs. oral finasteride

Finasteride reduces serum DHT by roughly 70% and has over 25 years of clinical data supporting its efficacy. It is FDA-approved, widely available as a generic, and costs a few dollars per month. Pyrilutamide does not lower serum DHT and may theoretically avoid the systemic side effects some men experience with finasteride. The tradeoff: pyrilutamide has far less clinical data, is not FDA-approved, and requires twice-daily topical application rather than a once-daily pill. For anyone currently stable on finasteride, there is no evidence-based reason to switch. For those who cannot tolerate finasteride or prefer to avoid systemic DHT reduction, pyrilutamide represents a potential future alternative.

vs. topical finasteride

Topical finasteride reduces DHT locally with lower (but not zero) systemic absorption compared to the oral form. Studies show it still reduces serum DHT by 20-30%, depending on concentration and formulation. Pyrilutamide does not reduce DHT production at all. It operates at the receptor level rather than the enzyme level. In theory, this means even less systemic antiandrogenic effect, though head-to-head trials comparing the two do not yet exist.

vs. minoxidil

Minoxidil works through an entirely different mechanism (likely vasodilation and potassium channel activation) and does not interact with the androgen pathway at all. Pyrilutamide and minoxidil are not competing alternatives. They could theoretically be used together, similar to the well-established finasteride-plus-minoxidil combination. If pyrilutamide gains approval, a pyrilutamide-plus-minoxidil regimen would address both androgen receptor activity and follicular stimulation without any systemic DHT reduction.

The honest assessment: where the evidence stands

The scientific rationale is strong. Blocking androgen receptors at the follicle is a logical approach to preventing DHT-driven miniaturization without systemic hormone effects. The Phase II data is encouraging but limited: 123 participants, one ethnic population, 24 weeks. The Phase III data that will determine this compound's real-world efficacy and safety profile is not yet available.

Some patients are already obtaining pyrilutamide through compounding pharmacies or international importation. This carries real risks. Compounded formulations are not subject to the same manufacturing standards as FDA-approved drugs. Concentration, purity, and vehicle formulation can vary significantly between compounding sources. There is no standardized dosing protocol outside the clinical trial setting, and long-term safety data beyond 24 weeks does not yet exist in published, peer-reviewed literature.

Cost is another practical consideration. Compounded pyrilutamide currently ranges from $80 to $200+ per month depending on the source, concentration, and quantity. This is substantially more expensive than generic finasteride (often under $10/month) and comparable to or more than branded topical finasteride solutions. Without insurance coverage (which requires FDA approval), the cost barrier is significant for sustained long-term use.

What to track if you try pyrilutamide

If you and your dermatologist decide to try pyrilutamide (whether through a clinical trial or off-label sourcing), structured tracking becomes even more important than with established treatments. With finasteride, you have decades of data telling you what to expect at 3, 6, and 12 months. With pyrilutamide, you are generating your own dataset. Here is what to document:

• Baseline photos: Capture all standard angles (hairline, temples, crown, part line) under consistent lighting before your first application. These become your reference point for everything that follows.
• Monthly comparison photos: Same angles, same lighting, same time of day. The Phase II trial showed measurable results at 24 weeks, so plan for at least 6 months of tracking before drawing conclusions.
• Shedding observations: Some treatments trigger an initial shed as resting hairs are pushed out. Document whether this occurs and its duration. With pyrilutamide, the shedding pattern is not yet well characterized in published literature.
• Scalp reactions: Log any redness, dryness, itching, or irritation at the application site. Note severity (mild/moderate/severe) and duration. This data helps your dermatologist adjust the protocol if needed.
• Side effects: While Phase II data showed no systemic effects, you should still monitor and log any changes you notice. Individual responses can differ from group averages.
• Source and formulation details: Record the concentration, vehicle type, and source of your pyrilutamide. If you switch suppliers or formulations, note the change date so you can correlate any shifts in response.

Use the treatment progress tracker as your framework. The tracking structure works for any antiandrogen treatment. The key adaptation for pyrilutamide is extending your evaluation window to at least 6 months (matching the Phase II trial duration) before assessing efficacy, and maintaining especially detailed notes on tolerability since long-term safety data is still emerging.

Frequently asked questions

What is pyrilutamide?

Pyrilutamide (KX-826) is a topical androgen receptor degrader developed by Kintor Pharmaceutical. Applied to the scalp, it blocks DHT from binding to androgen receptors in hair follicles. Unlike finasteride or dutasteride, it does not reduce DHT production. It prevents DHT from exerting its effect at the follicle level.

Is pyrilutamide FDA approved?

No. As of early 2026, pyrilutamide has not received FDA approval. Phase III trials are ongoing in both China and the United States. Based on standard regulatory timelines, the earliest possible FDA approval would be 2028 or later. Some patients obtain it through compounding pharmacies, but this is off-label and unregulated.

How does pyrilutamide compare to finasteride?

Finasteride blocks the enzyme that creates DHT, reducing systemic DHT by about 70%. Pyrilutamide blocks the receptor that DHT binds to at the follicle, leaving systemic DHT levels unchanged. Finasteride has 25+ years of data and FDA approval. Pyrilutamide has one published Phase II trial with 123 participants. The mechanisms are complementary, not identical, and the evidence base is not comparable at this stage.

When will pyrilutamide be available?

In the US, availability depends on Phase III trial completion and FDA review. A realistic estimate is 2028 or later. In China, the timeline may be shorter given Kintor's more advanced trial status there. Some patients currently access pyrilutamide through compounding pharmacies or international sources, but these channels lack regulatory oversight and standardized quality controls.

The bottom line

Pyrilutamide represents a genuinely novel mechanism in hair loss treatment. Blocking the androgen receptor at the follicle rather than reducing DHT systemically is a sound scientific approach that could expand treatment options significantly, especially for patients who experience side effects from systemic DHT reduction. The Phase II data is promising. But promising Phase II data has failed to translate into approved treatments many times before.

The prudent approach: continue with proven, evidence-based treatments while monitoring pyrilutamide's Phase III results. If you choose to try it now through off-label channels, do so with your dermatologist's knowledge, track meticulously using the first 90 days tracker, and set a 6-month evaluation window before judging results. Visit our blog for ongoing coverage of emerging treatments and evidence-based tracking strategies.